Introduction
============

Hepatocellular carcinoma (HCC) is one of the malignancies with the poorest prognosis due to high incidence of metastasis that causes cancer-related deaths, worldwide. However, a lack of complete understanding of metastasis has significantly slowed advances in HCC treatment. The dissemination of cancer cells and subsequent colonization occur through a complex metastasis cascade. Tissue-specific homing of cancer cells largely depends on their adhesion to specific luminally expressed molecules on the vasculature [@B1]. In this multi-step metastasis cascade, integrin is important for acquiring epithelial-mesenchymal transition (EMT)-associated traits for cancer cell colonization [@B2]. The interactions between integrin αVβ3 on the cell surface and matrix proteins contribute to disseminated cell adhesion, cell survival, and colony formation, which characterize the metastatic phenotype [@B3]. The expression of integrin αV (ITGAV) has not only been associated with high rates of metastasis and poor prognosis [@B4] in epithelial cancers, but been linked to self-renewal in cancer stem cells [@B5]. Changes in the expression and activation of ITGAV, which impact adhesion-independent cell growth and survival in many primary and metastatic tumor cells, are pathologic hallmarks of cancer [@B5]-[@B7]. However, the mechanisms that control *ITGAV* expression remain largely unknown. Long non-coding RNA (lncRNA) has been shown to influence transcription of *cis*-linked genes or their neighboring genes [@B8]. Currently, the mechanisms by which non-coding gene activation impacts neighboring gene transcription still remain unclear [@B9].

The eukaryotic genome is folded into a hierarchy of topological chromatin domains and insulated structures [@B10]. Together with core histones, the linker histones (H1) help chromatin fold into higher-order structures [@B11]. Histone H1 is a class of structural proteins consisting of seven variants (H1.0, H1.1 to H1.5, and H1FX) in human somatic cells. The typical H1 structure consists of a central globular domain flanked by unstructured N- and C-terminal tails. The globular domain of H1 has a winged-helix fold structure with a preference for nucleosome recognition and associates with linker DNA [@B11], [@B12]. H1 binding to nucleosome mainly depends on hypoacetylation of core histones [@B12], which enables its binding of inactive genes. With distinct and preferential binding of chromatin or regulatory factors, linker histone may regulate gene profile differently. Here, we explored the role of lncRNA in promoting the migration and metastasis of HCC via *ITGAV* expression. AY interacted with histone H1FX and triggered chromatin remodeling on *ITGAV* promoter in HCC, leading to transcription initial complex for the *ITGAV* transcription.

Materials and Methods
=====================

Cell culture and transfection
-----------------------------

Hep3B, HepG2, SK-Hep1, LM3, BEL-7404, SMMC-7721, and human hepatocyte LO2 cells were from Cell Bank of Type Culture Collection of Shanghai Institute of Biochemistry & Cell Biology, Chinese Academy of Science, and cultured in Dulbecco\'s Modified Eagle\'s Medium (Gibco-Life Technologies) supplemented with 10% fetal bovine serum (FBS). Human umbilical vein endothelial cells (HUVECs) and human embryonic kidney cells (HEK-293T) were cultured in DMEM supplemented with 10% FBS. Hep3B, HepG2, SK-Hep1, LO2, and HEK-293T cells were authenticated by STR (short tandem repeats). BEL-7404, SMMC-7721 cells were identified by their morphological characteristics which were consistent with the report of establishment [@B13]. Cells were not contaminated by mycoplasma, and also not infected by bacteria or fungi. All cells were cultured in a humidified incubator with 5% CO~2~ at 37 °C. Plasmid DNA transfection assays were conducted when the confluence of incubated cells reached 60%-70%. For sulfatide treatment, cells were incubated at initial density 0.5x10^5^ cells/mL and treated with 2 μM galactocerebroside (Gal-Cer) or sulfatide (Sigma, St. Louis, Missouri, USA).

Plasmid construction
--------------------

The primers for plasmid construction are listed in the Supplemental Table [1](#SM0){ref-type="supplementary-material"}. The *ITGAV* promoter fragments were amplified by PCR as reported previously [@B14], and were cloned into a pGL3-basic vector at *Xho I* and *Kpn I* sites. Plasmids pSilencer4.1-sh*ITGAV* and pSilencer4.1-shAY were constructed based on two target sequences each and one was selected.

Human samples
-------------

Tumor tissues and adjacent non-tumor tissue samples were collected from patients (n = 57) at Fudan University Liver Cancer Institute, Shanghai Eastern Hepatobiliary Surgery Hospital, Third Affiliated Hospital of Zhongshan University, Shanghai Tenth People\'s Hospital, and First Affiliated Hospital of Wenzhou Medical University. Histological examination was used to confirm HCC diagnosis. Paraffin-embedded tissue blocks from 80 patients and corresponding hematoxylin and eosin-stained sections were overlaid for tissue microarray preparation by Super-Biotek (Shanghai, China). All studies involving human samples were approved by the Fudan Biomedical ethics committee (approval number 14000000020000024) and data privacy was maintained.

Quantitative reverse transcription PCR (qRT-PCR)
------------------------------------------------

Total RNA was isolated from various HCC cells, subcutaneous tumor tissues of nude mice using TRIzol reagent (Invitrogen, Life Technologies). The RNA extracted was subjected to reverse transcriptase reaction using M-MLV reverse transcriptase (Takara, Dalian, China) according to the manufacturer\'s instruction. The levels of lncRNA AY and *ITGAV* mRNA were measured by qPCR using the primers listed in the Supplemental Table [1](#SM0){ref-type="supplementary-material"}.

*In vitro* tube formation assay
-------------------------------

The μ-Slide Angiogenesis plate (Ibidi, Martinsried, Germany) was added with 10 μL/well Matrigel (BD Biosciences, CA, USA) and allowed to polymerize for 2 hours at 37 °C. At 48 hours after transfection, 1x10^4^ HUVEC cells were seeded in the slides and incubated for 4 - 6 hours at 37 °C prior to slide viewing.

MTT assay and colony forming assays
-----------------------------------

HCC cells (5×10^3^ cells/well) were seeded in triplicates in 96-well plates and treated with 2 μM 5-fluorouracil (5-FU; Shanghai Haipu Pharm, China), cisplatin (TargetMol, USA), sorafenib (Bayer, Germany), or sunitinib (Pfizer, USA). After incubation at 37 °C for indicated time, 20 μL of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution (5 mg/mL) was added in each well, and cells were incubated at 37 °C for an additional 4 hours. The formazan crystals were dissolved in dimethyl sulphoxide (DMSO), and measured using a spectrometer at a wavelength of 570 nm. For colony forming assay, 1000 cells were seeded on a 6-cm dish in triplicates and cultured for 2 weeks at 37 °C. The growth medium was refreshed every 2 days. After incubation, colonies were fixed using methanol, stained using crystal violet, and counted under an inverted microscope.

Immunostaining and histology
----------------------------

Frozen tissue sections were used for immunohistochemical analysis. Blood vessels in the tissue sections were stained with CD31 antibody. A rabbit anti-mouse ITGAV or αVβ3 antibody was used to identify the integrin αV subunit or αVβ3 in mouse subcutaneous tumors and liver metastasis foci, respectively. The details of antibodies used in immunohistochemistry are shown in Supplemental Table [2](#SM0){ref-type="supplementary-material"}.

Immunofluorescence
------------------

Cells fixed on the cover glass were blocked with goat serum and incubated with rabbit primary antibodies followed by goat anti-rabbit FITC-conjugated secondary antibodies. Details of antibodies in immunofluorescence assay are listed in the Supplemental Table [2](#SM0){ref-type="supplementary-material"}. Nuclei were stained using 4\'-6-diamidino-2-phenylindole (DAPI) (Sigma, St. Louis, Missouri, USA). Confocal laser scanning microscopy images were acquired by using LEICA TCS SP8 confocal microscope (Leica Microsystem, USA).

Flow cytometry analysis
-----------------------

Cell surface integrin αV and αVβ3 were assessed by flow cytometry analysis as reported previously [@B14]. The antibody information in flow cytometry analysis is shown in Supplemental Table [2](#SM0){ref-type="supplementary-material"}.

*In situ* hybridization
-----------------------

*In situ* hybridization (ISH) was performed to detect AY in HCC cells using Enhanced Sensitive ISH Detection Kit II (Boster, Wuhan, China) according to the manufacturer\'s instructions.

Western blotting
----------------

Cells were lysed using SDS lysis buffer (0.1% SDS, 1 x Protease Inhibitor Cocktail, Millipore, MA, USA). Proteins were separated using 10% SDS-polyacrylamide gels and transferred to polyvinylidene fluoride membranes. The blots were incubated with primary antibodies followed by incubation with horseradish peroxidase-conjugated secondary antibodies and visualized using the chemiluminescence detection kit (Millipore, MA, USA). Protein bands were quantitatively analyzed by measuring the grey value using Image J software. The information of antibodies used in Western blotting is summarized in Supplemental Table [2](#SM0){ref-type="supplementary-material"}.

Luciferase reporter assay
-------------------------

For luciferase assays, cells were co-transfected with pSilencer4.1-shAY or pcDNA3.1b-AY and firefly luciferase reporter constructs containing the integrin αV promoter in pGL3-basic vectors. The cell lysates were analyzed using a luciferase reporter assay system (Promega, Madison, USA).

Protein microarrays
-------------------

The T7 promoter was constructed into the upstream sequence of AY by PCR. RNAs were transcribed *in vitro* using MEGAscript T7 Kit (Ambion, USA) and labeled with fluorescent dye Cy5 using manufacturer\'s instructions. HuProt^TM^ 20K Human Protein Microarray (CDI Lab, Mayaguez, USA) was used for AY analysis.

RNA pull-down assays and RNA immunoprecipitation
------------------------------------------------

RNA pull-down analysis was performed as previous report [@B15]. In brief, Full-length AY or mutated AY RNA was in vitro transcribed using T7 RNA polymerase and labeled with biotin (Roche, Mannhein, Germany). Then cytoplasmic extracts prepared from Hep3B cells using RIPA buffer (150 mM NaCl, 0.5% sodium deoxycholate, 0.2% SDS, 1% NP40, 1% Triton X-100, 1mM EDTA, and 50 mM Tris pH 8.0) were incubated with in vitro transcribed and biotinylated RNA, which were then targeted with streptavidin beads (Vector Laboratories, CA, USA) and washed. The associated proteins were resolved by gel electrophoresis. RNA immunoprecipitation assays were performed as reported previously [@B9]. Hep3B cells were treated with 1% formaldehyde, dissolved in RIPA buffer, and supplemented with Recombinant RNase Inhibitor (Takara, Dalian, China) and Protease Inhibitor Cocktail (Millipore, MA, USA). The lysates were sonicated and then centrifuged at 13,800 g for 10 min. After preclearing, supernatants were incubated with indicated antibodies for 4 hours and subsequently incubated with protein G agarose (Millipore, MA, USA) for 2 hours. AY enrichment was analyzed using qRT-PCR. Antibody information used in these 2 assays is summarized in Supplemental Table [2](#SM0){ref-type="supplementary-material"}.

Chromatin immunoprecipitation (ChIP)
------------------------------------

ChIP was performed using EZ-ChIP^TM^ kit (Millipore, MA, USA) as described previously [@B4]. Chromatin Isolation by RNA Purification (ChIRP) was according to previous reports [@B16]. Primers used in ChIP-qPCR are listed in the Supplemental Table [1](#SM0){ref-type="supplementary-material"}.

Animal studies
--------------

All animal experiments were performed according to the Animals Ordinance and the institutional guidelines concerning animal use and care. They were approved by the Animal Ethics Committee, School of Basic Medical Sciences, Fudan University (permit number 20140226-001). SMMC-7721 cells (5x10^6^) stably overexpressing AY and mock cells were injected subcutaneously into 4-week old female BALB/c nude mice. Tumor size was determined by measuring the length and width, and tumor volume (mm^3^) was calculated thereafter. All mice were sacrificed 31 days after injection, and tumors from each animal were weighed and examined for metastasis and histopathological studies. For Matrigel plug assay, BALB/c nude mice (4 weeks of age) were given subcutaneous injections of 200 μL of Matrigel (BD Biosciences) containing 5×10^6^ SMMC-7721-AY4 stably overexpressing AY or SMMC-7721-Mock6 cells. Two weeks later, the plug was isolated, fixed and stained with CD31 antibody. For metastasis assay, 2x10^4^ SMMC-7721-AY4 cells and mock cells were injected into nude mice through tail vein. Four weeks later, all of nude mice were sacrificed and their livers and lungs were isolated for examination of metastatic foci and histology.

Statistical analysis
--------------------

The difference between individual groups was assessed by Mann-Whitney U test or Student\'s t-test. Overall survival was analyzed by the Kaplan-Meier plot. For Kaplan-Meier analysis, AY cutoff point was calculated based on the time-dependent ROC curve analysis using SPSS 22.0 (IBM Corporation, Armonk, NY, USA) rather than simply using the median. All data were presented as mean ± standard deviation (SD). *P* value less than 0.05 was defined as significant. Data were collected from at least three independent experiments (triplicates).

Results
=======

LncRNA AY927503 is highly expressed in HCC cells
------------------------------------------------

We compared the lncRNA profile in sulfatide-treated HCC cells with that of control cells using the ArrayStar lncRNA microarray V2.0 and observed a comprehensive set of differentially expressed lncRNAs (data not shown). Levels of lncRNA AY927503 (AY) were increased by more than 2-fold compared with control, which was further confirmed by polymerase chain reaction (PCR). Coding potential assessment tool (CPAT) and coding potential calculator (CPC) analyses indicated that the AY transcript had very low coding probability (Supplemental Figure [1](#SM0){ref-type="supplementary-material"}A). In a cohort of 53 pairs of HCC and adjacent non-tumor (NT) specimens, we found that HCC tissues showed significantly higher AY expression than the paracancerous NT tissues (*P* \< 0.001, Figure [1](#F1){ref-type="fig"}A, a & b). In another cohort of 80 patients with HCC, *in situ* hybridization assays in a tissue array showed that AY signals per cell were significantly higher in HCC tissues than in adjacent NT tissues (*P* \< 0.01, Figure [1](#F1){ref-type="fig"}B, a). Patients at T3 and T4 stages of HCC showed increased AY signals compared with patients at T1 and T2 stages (*P* \< 0.05, Figure [1](#F1){ref-type="fig"}B, b). Survival analysis of patients (n = 64) that were followed up showed that patients with low AY expression survived longer than those with high AY expression (*P* = 0.034, Figure [1](#F1){ref-type="fig"}B, c & d). Patients with large tumor sizes (\>3cm) showed higher AY levels than patients with small tumor sizes (*P* \< 0.05, Figure [1](#F1){ref-type="fig"}B, e). Patients with vascular tumor emboli showed higher AY levels than patients without tumor emboli (*P* \< 0.05, Figure [1](#F1){ref-type="fig"}B, f). Analysis of data from the cancer genome atlas (TCGA) HCC database also showed that HCC tissues had elevated AY expression compared with their paired NT tissues (*P* \< 0.001, N = 248, Figure [1](#F1){ref-type="fig"}C, a). Kaplan-Meier survival analysis showed that high AY levels were closely associated with poor overall survival in patients with HCC (N = 180,*P* = 0.0014, Figure [1](#F1){ref-type="fig"}C, b). AY broadly expressed in breast (N = 837), kidney (N = 448), lung (N = 488) and liver tissues. Like in HCC, AY showed higher expression in tumors than in normal tissues (Figure [1](#F1){ref-type="fig"}D). We also found that AY expression was significantly higher in MHCC97H (high metastatic potential) HCC cells than MHCC97L (low metastatic potential) HCC cells (*P* \< 0.05, Figure [1](#F1){ref-type="fig"}E, a). These suggested that increased AY expression was associated with metastasis of HCC.

AY promotes ITGAV expression
----------------------------

We have previously shown that sulfatide promoted metastasis of HCC by integrin αVβ3 via upregulation of ITGAV [@B14], [@B17]. We analyzed AY and *ITGAV* expression levels in seven liver cancer cell lines and human hepatocyte LO2 cell line. The expression profile of AY in Hep3B, HepG2, LM3, SMMC-7721, Huh7, LO2, BEL-7404, and SK-Hep1 cells was similar to that of *ITGAV*. We observed a close positive correlation between AY and *ITGAV* expression levels (Pearson correlation coefficient r = 0.8729, Figure [1](#F1){ref-type="fig"}E, b-d). We analyzed the expression levels of AY and *ITGAV* mRNA in tissue samples from 53 patients with HCC. Thirty six out of 53 HCC tissue samples showed significantly higher AY levels than adjacent NT tissues (*P* \< 0.01, Figure [1](#F1){ref-type="fig"}A, c). Of the 36 samples, 33 also expressed high levels of *ITGAV*. Five out of 17 HCC samples that showed lower AY levels than adjacent NT tissues also showed lower *ITGAV* levels (Figure [1](#F1){ref-type="fig"}A, d). Pearson Chi-square (χ^2^) test results showed a significant correlation between AY and *ITGAV* expression levels (*P* \< 0.05). TCGA data analysis also showed a close correlation between AY and *ITGAV* expression levels (N = 122, *P* \< 0.0001, Figure [1](#F1){ref-type="fig"}C, c). We ectopically expressed AY or specifically silenced/knocked out AY in HCC cells to study its influence on *ITGAV* expression. In HCC cells that overexpressed AY, *ITGAV* mRNA levels were increased by almost two-folds, but knockdown of AY sharply reduced *ITGAV* mRNA levels (Figure [2](#F2){ref-type="fig"}A). ITGAV protein levels were also enhanced in HCC cells that overexpressed AY and were significantly reduced in AY knockdown cells compared with that of control cells (Figure [2](#F2){ref-type="fig"}B). Immunofluorescence analysis showed that ITGAV and integrin αVβ3 expression on the cell surface was significantly increased in HCC cells that overexpressed AY and was decreased in AY knockdown cells (Figure [2](#F2){ref-type="fig"}C).

AY promotes metastasis-related behaviors in HCC cells
-----------------------------------------------------

Because angiogenesis is important for tumor metastasis, which is associated with integrin αVβ3, we performed the tube formation assay to investigate the role of AY in angiogenesis. We found that human umbilical vein endothelial cells (HUVECs) that overexpressed AY showed significantly more branching points (an indicator of angiogenesis) than mock cells (*P* \< 0.01, Figure [3](#F3){ref-type="fig"}A). Knockdown of *ITGAV* not only abolished the angiogenic effect of AY in HUVECs, but also reduced the branching points to a number lower than that of the mock group. However, overexpression of *ITGAV* restored the branching ability of HUVECs. The number of colonies formed in AY-transfected cells was significantly greater than that of the mock cells. However, the colony number was significantly reduced in cells that were silenced for AY compared with that of scramble control (Figure [3](#F3){ref-type="fig"}B, a). Overexpression of AY significantly increased cell viability (Figure [3](#F3){ref-type="fig"}B, b), but knockdown of *ITGAV* abolished this AY effect. In Hep3B cells, knockdown of AY significantly reduced cell vitality rate, but transfection of *ITGAV* or the AY construct rescued cell vitality rates (Figure [3](#F3){ref-type="fig"}B, b).

EMT is an important process that enables tumor cell migration and metastasis in HCC. We found that AY significantly reduced the expression levels of E-cadherin and enhanced the levels of N-cadherin, ZEB1, or Twist (Figure [3](#F3){ref-type="fig"}C, a & b). However, these AY effects were abolished by *ITGAV* knockdown. Conversely, knockdown of AY promoted E-cadherin but inhibited N-cadherin, vimentin, ZEB1 and Twist expression and *ITGAV* overexpression reversed this effect (Figure [3](#F3){ref-type="fig"}C, a & b). We also examined the role of AY in promoting cancer stem cell (CSC) traits and chemoresistance. We found that overexpression of AY enhanced the expression of stem cell markers OCT4 and SOX2. However, this effect was also abolished by *ITGAV* knockdown (Figure [3](#F3){ref-type="fig"}D, a & b). Conversely, AY silencing significantly reduced the expression levels of OCT4 and SOX2, but this effect was reversed by *ITGAV* overexpression. AY expression was significantly reduced in cells treated with 2 μM 5-fluorouracil (5-FU) compared with that in control cells (*P* \< 0.01, Figure [3](#F3){ref-type="fig"}E, a & b). However, the cell vitality of the cells treated with 2 μM 5-FU was significantly enhanced by the overexpression of AY and reduced by the silencing of *ITGAV* compared with that of the mock group (Figure [3](#F3){ref-type="fig"}E, c). Conversely, AY knockdown sharply inhibited cell vitality of Hep3B cells treated with 5-FU, but AY or *ITGAV* overexpression completely restored cell vitality after 48 hours (Figure [3](#F3){ref-type="fig"}E, d). The half maximal inhibitory concentration (IC50) for 5-FU was significantly elevated in HepG2 cells overexpressing AY compared with that in control cells. Knockdown of AY sharply decreased the IC50 of 5-FU in Hep3B cells (Figure [3](#F3){ref-type="fig"}E, e & f). Our results suggested that AY promoted HCC metastasis-related behaviors via regulating *ITGAV* expression.

AY promotes HCC metastasis
--------------------------

Using tumor xenografts, we studied the effects of lncRNA AY on tumor growth and metastasis *in vivo*. Based on AY and *ITGAV* levels, stable AY-overexpressing (AY4) and control (M6) cells were selected for tumor xenograft experiments (Figure [4](#F4){ref-type="fig"}A). We subcutaneously injected AY4 or M6 cells (5×10^6^ cells) into 4-week old female BALB/c nude mice (n = 10/group), and examined tumor sizes. We found that the tumors in the AY group were significantly larger and heavier than those in the control group (Figure [4](#F4){ref-type="fig"}B). The AY group showed higher AY and *ITGAV* mRNA levels and stronger staining of ITGAV and integrin αVβ3 (Figure [4](#F4){ref-type="fig"}C, a & b) than the control group.

Tumor tissues in the AY group showed more positive CD31 (blood vessel endothelial cell marker) staining than the control (Figure [4](#F4){ref-type="fig"}D, a). More CD31 positive cells were also observed in the Matrigel-plug of the AY group than the control group (Figure [4](#F4){ref-type="fig"}D, b). The AY group also showed significantly more metastasis foci in the liver and lung than the mock group (Figure [4](#F4){ref-type="fig"}E). Also, ITGAV staining was more intense in liver metastasis tissues in the AY group than that in the control group (Figure [4](#F4){ref-type="fig"}F). Our results suggested that AY promoted*ITGAV* expression and HCC metastasis *in vivo*.

AY enhances *ITGAV* gene transcription
--------------------------------------

We next performed *in situ* hybridization assay in HCC cells and observed that AY was localized either in the nucleus or in the cytoplasm (Figure [5](#F5){ref-type="fig"}A, a). To know whether AY interacted with *ITGAV* gene we further conducted chromatin isolation by RNA purification (ChIRP) experiments to pull down sonication-sheared genome DNA using biotinylated AY and noted that the *ITGAV* promoter was as part of the AY complex (Figure [5](#F5){ref-type="fig"}B), which suggested that AY interacted with the *ITGAV* promoter. We then performed luciferase reporter assays using the full-length *ITGAV* promoter (-1295 to +207) [@B14] to investigate the effect of AY on *ITGAV* promoter activity (Figure [5](#F5){ref-type="fig"}A, b). We found that AY overexpression significantly stimulated *ITGAV* promoter activity (Figure [5](#F5){ref-type="fig"}A, c) in SMMC-7721 (*P* \< 0.001), HEK-293T (*P* \< 0.01), and HeLa (*P* \< 0.001) cells. However, AY knockdown in these cells significantly reduced *ITGAV* promoter activity (Figure [5](#F5){ref-type="fig"}A, d). Full-length AY did not enhance tyrosine hydroxylase (*TH*) or *pGL3* promoter activities (Figure [5](#F5){ref-type="fig"}C, d), which suggested that AY specifically regulated *ITGAV* promoter activity.

AY domain-deletion experiments (Figure [5](#F5){ref-type="fig"}D) found that mutants 5 (1-671) and 4 (1-522) showed enhanced *ITGAV* promoter activity, similar to that of full-length AY (Figure [5](#F5){ref-type="fig"}C, a & b), but mutants 2 (1-371) and 1 (1-298) failed to show enhanced *ITGAV* promoter activity in both HEK-293T and SMMC-7721 cells. Mutant 3 (1-401) showed a partial stimulatory effect. These results indicated that the 371-522 domain of AY was important for the regulation of *ITGAV* promoter activity by AY. Consistently, mutant AY∆371-522, which lacked the 371-522 domain, showed no AY-induced *ITGAV* promoter activity (Figure [5](#F5){ref-type="fig"}C, c). Individual overexpression of the 371-522 segment of AY or the AY∆371-522 sequence failed to stimulate *ITGAV* promoter activity and transcription. We detected *ITGAV* expression in both BEL-7404 and SMMC-7721 cells only when full-length AY was overexpressed (Figure [5](#F5){ref-type="fig"}E, a & b). Similar results were observed with ITGAV protein expression (Figure [5](#F5){ref-type="fig"}E, c). Also, neither AY∆371-522 nor AY371-522 could individually promote wound closure rate (Figure [5](#F5){ref-type="fig"}E, d). Together, these results suggested that the 371-522 domain of AY was important, but not solely required, for AY-induced *ITGAV* promoter activity.

AY interacts with linker histone H1FX
-------------------------------------

RNA immunoprecipitation (RIP) and RNA pull-down analyses showed no significant interactions between AY and factors known to be important for *ITGAV* expression (8, 9, 21), such as STAT3, Sp1, BRD1, HBO1, MOZ, and HDAC8 (data not shown). Also, we didn\'t find AY interaction with ZNF282 in these two assays (data not shown). Therefore, we conducted mass spectrometry and high-throughput protein chip experiments to screen for proteins associated with AY. Histone 1FX (H1FX) and Ig kappa chain C region (IGKC) were identified by both mass spectrometry and protein chip assay. We excluded IGKC from further analysis due to statistical insignificance. RNA pull-down assays showed a direct interaction between AY and H1FX (Figure [6](#F6){ref-type="fig"}A, a). H1FX was also observed in the complex pulled down by odd or even pool of AY probes (Figure [5](#F5){ref-type="fig"}B). Of the six other histone H1 variants, H1.2, H1.3, and H1.4 precipitated in a complex with AY, but H1.0, H1.1, and H1.5 did not (Figure [6](#F6){ref-type="fig"}A, a). H1FX, H1.2, H1.3, and H1.4 also interacted with the AY371-522 domain (Figure [6](#F6){ref-type="fig"}A, b). In the AY deletion mutant, AYΔ371-522, H1FX levels were markedly reduced in the co-precipitation complex, but H1.2, H1.3, or H1.4 levels remained unaffected compared with the precipitate containing full-length AY. Our results suggested that the central domain of AY (371-522) interacted with H1FX.

AY binding to H1FX induces chromatin remodeling
-----------------------------------------------

We then tested H1FX occupancy of the *ITGAV* promoter by chromatin immunoprecipitation assays using five pairs of primers (Figure [6](#F6){ref-type="fig"}B, a). Interestingly, H1FX not only occupied the *ITGAV* promoter region from -1241 to -677 (Figure [6](#F6){ref-type="fig"}B, b), but was also observed on intron 1 and exons 1 & 2. RNA polymerase II (pol ll), however, occupied intron 1 and the upstream region from -894 to -492 (Figure [6](#F6){ref-type="fig"}B, d). AY overexpression significantly enhanced pol II occupancy in the upstream region, but H1FX occupancy on intron 1 and the upstream region from -894 to -492 was significantly reduced (Figure [6](#F6){ref-type="fig"}B, c & e). We also observed reduced occupancy of H3K27Me3, a histone H3 containing a tri-methylated lysine 27 residue, on the promoter (Figure [6](#F6){ref-type="fig"}C). AY significantly enhanced the occupancy of H3K4Me3 and acH3K9/14 on the *ITGAV* promoter (Figure [6](#F6){ref-type="fig"}C). H1FX silencing abolished stimulation of the *ITGAV* promoter by AY overexpression (Figure [6](#F6){ref-type="fig"}D, a). Silencing of H1.2, H1.3, or H1.4 did not have any effect on *ITGAV* expression and their occupancy on the *ITGAV* promoter was unchanged by AY overexpression (Figure [6](#F6){ref-type="fig"}D, a & b). These results suggested that AY interaction with H1FX induced core histone modification on *ITGAV* promoter.

Core histone modification induced by AY repels H1FX binding
-----------------------------------------------------------

Binding of linker histones to the DNA/nucleosome is enabled by histone chaperone proteins [@B18]. By mass spectrometry, we noted histone 1 chaperone, nucleolin (NCL), as part of the AY complex. We then tested whether AY regulation of H1FX occupancy on the *ITGAV* promoter was mediated by NCL. RNA pull-down assays showed that NCL interacted with both full-length AY and mutant versions of AY (AY371-522, AY∆371-522) (Figure [6](#F6){ref-type="fig"}A). NCL was also observed in an immunoprecipitation complex with H1FX, but was not enhanced by AY overexpression (Supplemental Figure [2](#SM0){ref-type="supplementary-material"}B). RNase treatment did not reduce the interaction of NCL with H1FX (Supplemental Figure [2](#SM0){ref-type="supplementary-material"}C). However, overexpression of AY significantly reduced the enrichment of NCL on the *ITGAV* promoter (from -894 to -492) (Figure [6](#F6){ref-type="fig"}D, b). Silencing of NCL also diminished the stimulatory effect of AY on *ITGAV* transcription (Figure [6](#F6){ref-type="fig"}D, a). We further found that ectopic expression of AY significantly strengthened the occupancy of PCAF, a histone acetyltransferase for acH3K9/14, but reduced the enrichment of SIRT1, a histone deacetylase, on the *ITGAV* promoter region of -894 to -677 (Figure [6](#F6){ref-type="fig"}E). Data from ChIP sequence indeed showed that SIRT1 and PCAF were bound on *ITGAV* locus (Figure [6](#F6){ref-type="fig"}F). Our results suggested that AY recruited histone modification enzymes and induced regional histone modification that repelled the NCL/H1FX binding and activated*ITGAV* promoter.

Discussion
==========

Long non-coding RNAs are transcripts that do not code for protein sequences, but their functions are well characterized. In this study, we identified a novel lncRNA, AY927503 (AY), which was highly expressed in HCC cells. High expression levels of AY were closely associated with poor prognosis and metastasis in patients with HCC. Levels of AY correlated with the expression of*ITGAV*. Also, overexpression of AY promoted cell migration, tube formation, EMT process, and 5-fluorouracil resistance *in vitro* and tumorigenesis, metastasis, or angiogenesis *in vivo*. These AY effects were abolished by knockdown of *ITGAV*. ITGAV is one of the members of the integrin family and is encoded by the *ITGAV* gene on chromosome 2. We have previously shown that elevated sulfatide levels in HCC cells enhanced integrin αVβ3 expression by promoting *ITGAV* transcription [@B14], [@B17], [@B19]. Here, we showed a novel role for lncRNA AY as a pioneer factor in regulating *ITGAV* gene transcription and promoting metastasis.

Targeted gene transcription is controlled by transcription factors that mediate the binding of chromatin-modifying machinery to specific genomic loci [@B10]. However, transcription factors cannot access the cognate sites in the compacted chromatin without chromatin remodeling [@B20]. Pioneer transcription factors (PFs) have the ability to bind to the transcription site prior to chromatin remodeling [@B10]. In fact, PFs can penetrate repressed chromatin and initiate chromatin decompaction to access the cognate DNA sequences in nucleosomes that are locked by linker histones [@B21]. RNAs have been shown to interact with proteins or small RNAs, little is known about lncRNA interaction with target gene in chromatin. In this study *ITGAV* promoter was identified in the AY complex. Also AY significantly induced chromosome remodeling on *ITGAV* promoter and stimulated the promoter activity.

Although lncRNAs are involved in many biological processes, most lncRNAs show limited evolutionary conservation of motifs or folding structures that are independent of the RNA sequence [@B22]. We identified the central domain of AY (AY371-522), which was critical for its stimulation of the *ITGAV* promoter and interaction with histone 1FX (H1FX). Analysis of the AY secondary structure by RNAfold (an online prediction algorithm) (Figure [5](#F5){ref-type="fig"}C) revealed a distinct molecule that was shaped like an umbrella, in which the central domain, AY371-522, constituted the handle section that interacted with H1FX.

Ectopically expressed AY interacted with H1FX and reduced H1FX occupancy on the *ITGAV* gene promoter. AY may reduce the binding affinity between H1FX and the DNA/nucleosome, which could result in the displacement of H1FX from the *ITGAV* promoter region. Binding of linker histones to the nucleosome is enabled by histone chaperone proteins [@B18]. Interestingly, we found that histone chaperone, NCL, directly interacted with AY, also a RNA binding protein, and not just via the H1FX-NCL complex [@B18].

Notably AY significantly reduced NCL enrichment on the *ITGAV* promoter as well. NCL preferentially binds to H3K4Me2 and not H3K4Me3 [@B23]. H1FX is usually associated with the poorly acetylated core histone-enriched regions of genomic DNA [@B12], [@B24], [@B25], but has low binding affinity for promoters with highly acetylated histones [@B26]. We showed that AY significantly enriched H3K4me3 and acH3K9K14 on the *ITGAV* promoter. It is possible that these proteins repel NCL/H1FX from the *ITGAV* promoter regions. Reduced occupancy of H1FX might create an open chromatin state which allows interaction between permissive chromatin enriched in H3K4me3 and the pre-initiation complex for transcription of *ITGAV*. H1FX is often associated with histone deacetylase [@B12] and its histone tail impedes H3 access by PCAF, which prevents modification of H3 [@B2]. We observed that AY significantly enhanced PCAF and acH3K9/14 enrichment on the *ITGAV* promoter, and reduced SIRT1 occupancy. It is possible that AY interaction with H1FX alters the position of the H1FX tail, which allows PCAF to access H3 on the *ITGAV* promoter.

In conclusion, high levels of AY promoted HCC metastasis and were correlated with poor prognosis in patients with HCC. Thus, AY becomes a novel potential molecular signature for metastasis of HCC. The promotion of metastasis by AY was associated with activation of*ITGAV* transcription by recruitment of the chromatin-modifying machinery to the *ITGAV* promoter and reducing H1FX binding.
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HCC

:   human hepatocellular carcinoma

lncRNA

:   long non-coding RNA

AY

:   AY927503

ITGAV

:   integrin αV

NCL

:   nucleolin

EMT

:   epithelial-mesenchymal transition

pol II

:   RNA polymerase II

![**AY was highly expressed in HCC tissues and cells. A.** Quantitative RT-PCR analysis of lncRNA AY expression in HCC tissues (T) and matching adjacent non-tumor (NT) liver tissues (a,c). Significant differences in median AY expression levels between HCC and NT (*P* \< 0.001) by Mann-Whitney test (b). Correlation analysis between integrin αV (ITGAV) and AY expression levels (d). -, *ITGAV* RNA expression level was lower in HCC tissue than adjacent NT tissue; +, *ITGAV* RNA expression level was higher in HCC tissue than adjacent NT tissue. The differences reached significance (*P* \< 0.05) by Pearson χ^2^ test. **B.** *In situ* hybridization analysis of AY expression in 80 paired HCC tissues and adjacent non-tumor (NT) tissues. The positive hybridization signals per cell were compared between HCC and NT tissues (a). Kaplan-Meier survival analysis of patients with low AY expression (low) and high AY expression (high) based on threshold 4.083 calculated by time-dependent ROC curve analysis (c & d). Comparison of AY expression between early (T1, 2) and late (T3, 4) TNM stage tumors (b); between patients with large (\> 3 cm) and small (\< 3 cm) tumor sizes (e); and between patients with vessel carcinoma embolus and without embolus (f). **C.** AY expression analysis of 180 HCC cases from the TCGA database (a). Kaplan-Meier analysis of overall survival of 180 patients with HCC based on AY expression (0.635 as AY cutoff calculated by time-dependent ROC curve analysis) (b). Pearson correlation analysis between AY expression and *ITGAV* expression (c). **D.** AY expression in various tissues and tumors from TCGA database. BRCA Breast invasive carcinoma, BLCA Bladder urothelial carcinoma, CESC Cervicalsquamous cell carcinoma and endocervical adenocarcinoma, HNSC Head and neck squamous cell carcinoma, KIRC Kidney renal clear cell carcinoma, KIRP Kidney renal papillary cell carcinoma, LIHC Liver hepatocellular carcinoma, LUAD Lung adenocarcinoma, LUSC Lung squamous cell carcinoma, THCA Thyroid carcinoma, PRAD Prostate adenocarcinoma, STAD Stomach adenocarcinoma, UCEC Uterine corpus endometrioid carcinoma, LGG Brain lower grade glioma, COAD Colon adenocarcinoma, GBM Glioblastoma multiforme, OV Ovarian serous cystadenocarcinoma, READ Rectum adenocarcinoma, SKCM Skin cutaneous melanoma. **E.** QRT-PCR analysis of AY expression in HCC cells with high (MHCC97H) and low (MHCC97L) metastatic potential (a). AY and *ITGAV* expression was analyzed by qRT-PCR in various liver cancer cell lines and human hepatocytes, LO2 (b & c). Pearson correlation analysis between AY and *ITGAV* RNA expressions (d). Data are representative of three independent experiments. \*, *P* \< 0.05; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001.](thnov09p4421g001){#F1}

![**AY enhanced the expression of *ITGAV* in HCC cells. A.** QRT-PCR analysis of RNA levels of AY and *ITGAV* in the indicated cells that were transfected with pcDNA3.1b-AY (AY) and pcDNA3.1b (Mock), respectively (a). Relative RNA levels of AY and *ITGAV* were analyzed by qRT-PCR at 24 hours after AY-targeted short hairpin \#1 & \#2 transfection (b). **B.** In the indicated cells transfected with AY, shAY or corresponding control, the protein levels of ITGAV were examined by Western blotting (upper) and quantitated (lower). **C.** Representative fluorescence microscope images (100×) of ITGAV immunostaining at 48 hours after transfection with pcDNA3.1b-AY and pcDNA3.1b, respectively (a & b). Flow cytometry measurements of ITGAV or αVβ3 on cells after ectopic expression and silencing of AY, respectively (c). Data are representative of three independent experiments. \*, *P* \< 0.05; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001.](thnov09p4421g002){#F2}

###### 

**AY promoted HCC cell angiogenesis and proliferation. A.** Representative micrographs of HUVEC tube formation after AY overexpression or AY silencing (left). Quantification of the branching points (right). Original magnification: 10×. **B.** Colony formation assay in the cells overexpressing AY, AY knockdown and AY rescue cells and quantitative analysis (a). Cell vitality measurements in cells with AY overexpression, knockdown, or rescue (b). **C.**&**D.** EMT-related proteins and stem cell marker proteins were analyzed by Western blotting in indicated cells with AY overexpression or silencing (a). Quantification using Image J software was statistically summarized in the lower panel (b). **E.** Quantitative RT-PCR analysis of AY expression in the cells treated with various chemotherapy agents at a concentration of 2 μM (a & b). Cell vitality measurements of AY-overexpressing or AY-silenced HCC cells treated with 2 μM of 5-FU by MTT assays (c & d). IC50 value was determined in transfected cells and treated with various concentrations of 5-FU for 72 hours (e & f). Data are representative of three independent repeats. \*, *P* \< 0.05; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001.

![](thnov09p4421g003)

![](thnov09p4421g004)

![**AY promoted HCC cell growth and metastasis. A.** Validation of AY and *ITGAV* expression in stably transfected cell lines by qRT-PCR (upper) and Western blotting (lower), respectively. **B.** Representative images of nude mice and subcutaneous tumors (a & c). Volume and weight measurements of subcutaneous tumors derived from SMMC-7721 cells stably transfected with pcDNA3.1b (Mock6) and pcDNA3.1b-AY (AY4) (b). **C.** The AY and ITGAV expression in the implanted tumors were analyzed by qPCR (a). Representative micrographs of immunohistochemical staining with ITGAV and integrin αVβ3 antibodies in the implanted subcutaneous tumors (b & c, bar = 100 μm). The boxed field was amplified in the lower panel (bar = 20 μm). **D.** Representative images of immunohistochemical staining of CD31 in the subcutaneous tumor (a, bar=100 μm) and the Matrigel-plug (b, bar = 20 μm). Quantitative analysis of the microvascular density in AY-overexpressing cells (right). **E.** Representative images of lungs and livers (left) from nude mice at 4 weeks after tail vein injections with stably transfected Mock6 and AY4 cells. Images of H&E-staining (middle) and quantitative analysis of metastasis foci (right). Bar = 100 μm. **F.** Representative images of immunohistochemical ITGAV staining in liver metastatic foci (original magnification: 10×, bar = 100 μm). Boxed fields are shown at 40× magnification (bottom, bar = 20 μm). Data are representative of three independent experiments. \*, *P* \< 0.05; \*\*, *P* \< 0.01.](thnov09p4421g005){#F4}

![**AY up-regulated *ITGAV* transcription. A.** Representative micrographs of AY *in situ* hybridization and fluorescent *in situ* hybridization (a). Arrows indicate hybridization spots. Transcription activity analysis of the *ITGAV* core promoter region (-1295 \~ +207) in 3 cell lines by luciferase reporter assay (b). Effect of AY expression on transcriptional activity of the *ITGAV* promoter using luciferase reporter assay (c & d). **B.** A schematic diagram of the Biotin-AY pull-down experiment (upper). PCR identification of *IGTAV* promoter sequence in the DNA complex pulled down by biotinylated AY. Western analysis of H1FX in the complex pulled down by biotinylated AY probes (lower). Odd, odd pool, Even, even pool of AY probes. LacZ probe as negative control. **C.** Effect of AY truncation on *ITGAV* promoter activity in HEK-293T and SMMC-7721 cells by luciferase reporter assay (a & b). Analysis of AY371-522 regulation on *ITGAV* promoter activity (c). The effect of AY overexpression on the unrelated pGL3 promoter and human tyrosine hydroxylase promoter (TH PMT) (d). PMT, promoter; ∆, deletion mutation. **D.** A schematic diagram of AY truncations that were constructed into pcDNA3.1b for overexpression (a). Predicted secondary structure for AY by RNAfold (<http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi>) (b). The AY371-522 domain is marked by a red dotted circle. **E.** Quantitative comparative analysis of ITGAV expression between cells overexpressing full-length AY, AY371-522, AY△371-522, and mock control by qRT-PCR and Western blotting (a, b & c). Wound closure was analyzed in cells overexpressing full-length AY, AY371-522, and AY△371-522 (d). Data are representative of three independent repeats. \*, *P* \< 0.05; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001.](thnov09p4421g006){#F5}

![**AY interacted with H1FX. A.** Analysis of histone 1 proteins, NCL, or U1SnRNP in AY RNA pull-down assays. **B.** A schematic diagram of primer design for ChIP analysis of the *ITGAV* promoter (a). ChIP analysis of H1FX and RNA polymerase II (RNA pol II) binding on the *ITGAV* promoter regions in BEL-7404 cells overexpressing AY (b-e). GAPDH promoter (GAPDH pro) and IgG served as a negative control. **C.** ChIP-qPCR/PCR analysis of acH3K9/14, H3K4Me3, and H3K27Me3 occupancy on the *ITGAV* promoter (-894 \~ -677) in BEL-7404 cells overexpressing AY. **D.** QPCR analysis of AY and ITGAV expression levels in cells silenced for H1 variants and overexpressing AY (a). H1.2, H1.3, H1.4, or NCL interaction with the*ITGAV* promoter (-894 \~ -677) was analyzed by ChIP in cells with AY overexpression (b). **E.** ChIP-qPCR analysis of the enrichment of PCAF and SIRT1 in BEL-7404 cells overexpressing AY. **F.** ChIP-Seq reads from NCBI GEO database (GSE94403, GSE15735) and alignment to human genome and transcriptome (GRCh37/hg19, Ensemblv71). Data are representative of three independent repeats. \*, *P* \< 0.05; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001.](thnov09p4421g007){#F6}
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